BoB@JPM: Nima Farzan, Latigo Biotherapeutics

We love to hear from our listeners. Send us a message. In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company"s mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission. It"s a timely and important conversation that explores how these selective inhibitors could provide effective pain relief without the addiction risks and side effects of traditional opioids. In addition to the social and medical implications of Latigo"s work, we discuss investor perceptions about pain management as a commercial opportunity and how Latigo is differentiating from traditional approaches by focusing on safety and tolerability rather than just efficacy The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/